Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.

about

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.

Item

http://www.wikidata.org/entity/Q55217694

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Angiogenesis Inhibitors for th ...... Randomized Controlled Trials.

@en

Angiogenesis Inhibitors for th ...... Randomized Controlled Trials.

@nl

type

Item

label

Angiogenesis Inhibitors for th ...... Randomized Controlled Trials.

@en

Angiogenesis Inhibitors for th ...... Randomized Controlled Trials.

@nl

prefLabel

Angiogenesis Inhibitors for th ...... Randomized Controlled Trials.

@en

Angiogenesis Inhibitors for th ...... Randomized Controlled Trials.

@nl

P1476

Angiogenesis Inhibitors for th ...... Randomized Controlled Trials.

@en

P2093

Guiling Li

http://www.w3.org/2001/XMLSchema#string

Haihong Wang

http://www.w3.org/2001/XMLSchema#string

Lifen Zheng

http://www.w3.org/2001/XMLSchema#string

Tie Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Targeted anti-vascular therapies for ovarian cancer: current evidence

Quantifying heterogeneity in a meta-analysis

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

SEOM guideline in ovarian cancer 2014.

Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

P304

903-914

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1097/IGC.0000000000001258

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29561301

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5976222

http://www.w3.org/2001/XMLSchema#string